GENEVA, July 2 -- LARIMAR THERAPEUTICS, INC. filed a patent application (US2025/059983) for “TAT-FXN FUSION PROTEIN FOR USE IN THE TREATMENT OF FRIEDREICH'S ATAXIA”. With publication no. WO/2026/136463, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 38/17
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....